Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $69 price target on Integra LifeSciences after the company reported Q2 earnings results that were "ahead of expectations," with guidance the analyst believes is "likely conservative." O'Brien was also positive that the company's integration efforts look to be moving in the right direction, that...
I am in the market for stocks who have rallied hard and are now extremely overextended and vulnerable to a corrective sell off. IART is one such candidate. Anyone long in this trade is probably in the money and not wanting to lose a good profit. Punters may be wanting to buy hoping for another strong advance that will not materialise until a correction takes...
